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Background/aim: To examine the relationship of inherited thrombophilia and other thrombotic risk factors with preeclampsia (PE) in
a population of pregnant Turkish women.
Materials and methods: This was a case cross-sectional study in which 70 women with PE and 60 normal pregnant women were studied
to find out the frequency of women with risk factors including inherited thrombophilia among preeclamptic cases.
Results: Hemoglobin, platelet count, uric acid, vitamin B12, folic acid, copper, homocysteine, plasminogen activator inhibitor-1,
fibrinogen, protein S, protein C, activated protein C resistance values show significant differences in women with PE in comparison to
women with normal pregnancy.
Conclusion: There may be a link between inherited thrombophilia and PE, at least in a sample of Turkish pregnant women. We also
propose that the association between thrombophilia and PE is stronger than suggested previously. Furthermore, copper is selectively
elevated in women with PE as an independent marker.
Key words: Copper, homocysteine, plasminogen activator inhibitor-1, protein S, activated protein C resistance

1. Introduction
Preeclampsia (PE) is a disorder of pregnancy associated
with widespread vascular endothelial malfunction and
vasospasm. The pathophysiology of PE likely involves
both maternal and fetal/placental factors. Attention has
been focused on the link between inherited thrombophilia
and PE. The results of previous studies are controversial,
with some confirming (1–3) and others denying the link
between the two (4–6).
The heterogeneity among study results is undeniable.
Very few studies have mentioned the possible influence of
confounders such as ethnicity (7,8).
There is considerable evidence concerning trace
elements of serum level changes associated with PE.
Copper (Cu) is an essential cofactor for the enzymes
catalase, superoxide dismutase, and cytochrome oxidase,
and its deficiency can lead to a variety of vascular and
nutritional disorders (9). There are studies showing higher
(9), similar (10), or even lower levels of Cu (11) in the
circulation of women with PE in comparison to healthy
pregnant women.
* Correspondence: mehtappolat1977@yahoo.com
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The objective of this study was to examine the
relationship between inherited thrombophilia and other
thrombotic risk factors and PE in a population of pregnant
Turkish women.
2. Materials and methods
One hundred and thirty pregnant women who presented
to Gazi University
Medical School’s Department of Obstetrics between
October 2002 and November 2004 were categorized in the
third trimester of their pregnancies into 2 groups. Group
1 and group 2 included 70 women with preeclampsia
(group 1: study group) and 60 normotensive pregnant
women (group 2: control group), respectively. The clinical
data and blood samples were collected prospectively, but
laboratory work-up and data evaluation were achieved
retrospectively, without any intervention. Universal
principles of the Helsinki Declaration were applied in this
nonbiomedical case control study.
The inclusion criteria were nulliparity and having a
normal 50-g glucose loading test for both groups. Blood
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pressure measurement equal to or more than 140/90
mmHg (at least twice over a 6-h period), and proteinuria
(more than 0.3 g/24 h or more than +2 protein in a spot
urine test) were additional requirements for group 1.
Multiparous women and women with preexisting
essential hypertension, diabetes mellitus, liver, kidney
or metabolic diseases, any history of current drug use
excluding iron supplements, excessive physical activity, a
history of recurrent miscarriage, intrauterine fetus demise,
or personal and family history of thromboembolic disease
were excluded from both groups.
Regarding clinical follow up, all women were
examined every 2 to 3 weeks between 28 and 36 weeks and
weekly thereafter, but the optimal frequency and timing
of prenatal care visits especially in the PE group were
determined according to the needs and risk status of each
woman and her fetus. Additional ultrasound examinations
following a routine one performed between 18 and 22
weeks were done according to the presence of maternal or
fetal indications. Whenever the health of the mother and
the fetus were endangered by severe PE, induction of labor
and early delivery, either vaginally or by cesarean section,
was achieved.
Blood samples were taken upon admission to hospital
following 6 h of fasting for the following measurements:
hemoglobin (Hb), hematocrit (Htc), platelet count (PLT),
serum albumin (Alb), uric acid (UAC), creatinine (CR),
Cu, homocysteine (Hcy), vitamin B12 (vit B12), folic
acid (FOA), fibrinogen (FBN), protein C (PC), protein
S (PS), antithrombin III (AT III), activated protein C
resistance (aPCR), and plasminogen activator inhibitor-1
(PAI-1). All tests were carried out at the hospital’s central
laboratory, except thrombophilia markers. Atomic
absorption spectrometry (AA 6701F Atomic Absorption
Flame Emission Spectrophotometer, Shimadzu, Japan)
was used to measure Cu, and high performance liquid
chromatography (HPLC) (Waters, Germany) was used to
measure Hcy.
For thrombophilia tests, 10 mL of blood was placed
in EDTA vacutainer tubes, kept on ice and centrifuged at
2500 rpm for 10–30 min within 30 min of the sample being
drawn, and the plasma was carefully extracted and frozen
to –70 °С and then transferred to the hospital laboratory
on dry ice. The sample tubes were numbered without
any patient identification so that the laboratory could be
blinded. Thrombophilia markers were investigated in the
hospital’s central genetics laboratory. The STA - Staclot
aPCR kit (Diagnostica Stago, Asnieres, France) was
used for the assessment of the aPCR in plasma. Plasma
samples whose clotting times were ≥120 s or <120 s were
considered aPCR negative or aPCR positive, respectively
(8). Asserachrom (Diagnostica Stago, Asnieres, France)
ELISA kit for PAI-1, STA LIATEST immunoturbidimetric

assay kit (Diagnostica Stago, Asnieres, France) for protein
C & S, and STA Antithrombin III assay were used.
The statistical analyses were conducted with the
Statistical Package for the Social Sciences (SPSS/PC-11)
(SPSS Inc. Chicago, IL, USA). All data were provided
on an average ± standard deviation basis. The statistical
analysis of the differences between the patient and control
groups for the parameters showing normal distribution
(PC, aPCR, PAI-1) was done with a t-test. The Mann–
Whitney U test was used to make comparisons among the
parameters that did not demonstrate normal distribution.
The mean values of Hcy, Cu, PAI-1, PS, PC, AT III, and
aPCR in preeclamptic blood samples were defined as
abnormally high or as abnormally low if the measured
values were more than 95% or less than 5% of the average
levels measured in the control group, respectively. The
groups were then compared using Pearson’s chi-square
test. A value of P < 0.05 was considered to be statistically
significant.
3. Results
PE (group 1) and normotensive control (group 2)
pregnant women had similar ages and comparable
smoking and Turkish coffee drinking habits. Body weight
and BMI values were higher in PE women than in the
control group (Table 1). Further, PE women had higher
average systolic/diastolic blood pressure measurements
as expected, shorter duration of pregnancy, lower birth
weight, and newborn Apgar scores when compared with
the control group (Table 2). Out of the 70 PE women, 19
(27%) revealed intrauterine growth restriction (IUGR)
fetuses, an additional 2 (2.85%) had intrauterine ex fetuses,
and 2 (2.85%) had placental abruption (PLABR). Such
complications were not encountered in any of the control
cases. Labor had to be induced more frequently in the PE
group. Cesarean section rather than vaginal delivery was
the preferred mode of delivery in both groups (Table 3).
Regarding the laboratory results, PC, vit B12, and FOA
levels were lower and Hb, UAC, and Cu values were higher
in Group 1 as compared to Group 2. The mean values of
Htc, Alb, and CR were similar between the groups (Table
4). In terms of coagulation factors, PAI-1, aPCR, Hcy, and
FBN values were higher and mean PS values were lower
in the PE patients when compared to the normal control
group (Table 5). Table 6 reveals the cut-off levels of each
parameter and the percentage of women with abnormal
test results in the PE and control groups. As seen from the
data, Cu was elevated in 85.7%, PAI-1 in 77.1%, aPCR in
31.4%, and Hcy in 28.6% of the patients in the PE group,
while PS was suppressed in 52.9%. In Table 7, relative risk
ratios of developing PE with abnormal thrombophilia
markers and Hcy and Cu blood levels (odds ratios and
95% confidence intervals) are demonstrated.
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Table 1. Epidemiological characteristics of women in preeclamptic and control groups.
Parameter

Preeclampsia(Gr I)

Control (Gr II)

P

Women (n)

70

60

Age (year)

28.92 ± 4.71

29.4 ± 3.48

>0.05

Weight (kg)*

70.6 ± 10.74

65.9 ± 5.32

<0.01

BMI (kg/m2)*

26.79 ± 4.42

24.83 ± 1.67

<0.01

Nonsmoker

39 (56%)

36 (60%)

>0.05

Smoker < 10/ day

5 (7%)

3 (5%)

>0.05

Smoker ≥ 10/ day

26 (37%)

21 (35%)

>0.05

Non-coffee drinker

37 (53%)

32 (53%)

>0.05

Turkish coffee 1 cup/day

5 (7%)

3 (5%)

>0.05

Turkish coffee ≥2 cup/day

28 (40%)

25 (42%)

>0.05

BMI: Body mass index
Table 2. Clinical characteristics of women in preeclamptic and control groups (mean±SD).
Parameter

Preeclampsia(Gr I)

Control (Gr II)

P

Women (n)

70

60

Systolic BP (mmHg)*

162 ± 12.17

106 ± 17.38

<0.01

Diastolic BP(mmHg)*

99 ± 12.17

67 ± 8.89

<0.01

Duration of Pregnancy(wk)*

34.2 ± 2.64

37.3 ± 2.26

<0.01

Birth weight (gr) *

2615 ± 667.9

3128 ± 325.9

<0.01

Apgar (1. minute)*

8 ± 1.44

9 ± 0.37

<0.05

Apgar (5. minute)*

8 ± 1.44

9 ± 0.37

<0.05

BP: Blood pressure
Table 3. Labor characteristics and mode of delivery in women with preeclampsia and control groups.

Parameter

Preeclampsia(Gr I)
n

Control (Gr II)
%

%

P

Women (n)

70

60

Induction of labor*

13

18.6

2

3.3

<0.001*

Vaginal delivery

20

28.6

24

40

0.141

Cesarean delivery

50

71.4

36

60

0.141

4. Discussion
In our study, all of the pregnant women in both the PE
and control groups were young and nulliparous with
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single fetuses, without individual risk factors like personal
history of chronic hypertension, diabetes mellitus, renal
or any autoimmune diseases, or family history of PE.
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Table 4. Laboratory parameters of women in preeclamptic and control groups (mean±SD).
Parameter

Preeclampsia(Gr I)

Control (Gr II)

P

Women (n)

70

60

Hemoglobin (gr/dl)

11.79 ± 1.35

11.48 ± 1.47

0.013

Hematocrit (%)

34.99 ± 3.28

35.04 ± 3.10

0.842

Platelet/μL

198.421 ± 61.276

224.416 ±53.397

0.002

Albumin (mg/dl)

3.36 ± 0.43

3.44 ± 0.19

0.292

Creatinine (mg/dl)

0.68 ± 0.11

0.70 ± 0.09

0.181

Uric acid (mg/dl)

3.79 ± 1.42

3.06 ± 0.38

0.001

Vit. B12 (pg/ml)

223.83 ± 95.15

276.83 ± 69.80

0.001

Folic acid (ng/ml)

10.53 ± 4.11

11.32 ± 5.40

0.017

Cupper (μgr/dl)

210.95 ± 56.58

121.21 ± 25.08

0.001

Table 5. Thrombophilia markers and serum homocysteine levels in women with preeclampsia and control
groups (mean±SD).
Parameter

Preeclampsia(Gr I)

Control (Gr II)

P

Women (n)

70

60

Fibrinogen (mg/dl)

422.28 ± 85.49

327.35 ± 66.63

<0.001

Homocysteine (μmol/L)

10.5 ± 3.6

7.25 ± 2.44

<0.001

Protein C (%)

101.58 ± 18.33

109.70 ± 16.80

0.825

Protein S (%)

55.55 ± 28.9

68.48 ± 17.22

<0.001

Antithrombin III (%)

87.14 ± 21.46

90.15 ± 13.08

0.740

PAI-1 (ng/dl)

84.06 ± 32.35

30.53 ± 12.14

<0.001

APCR (sec) (pg/ml)

121.39 ± 33.17

99.22 ± 20.90

<0.001

aPCR: Activated protein C resistance
Table 6. The cut off levels and the percentage of women with abnormal test results in the preeclamptic and control patient groups.
Parameter
Women (n)
Protein S (%)
PAI-1 (ng/dl)
APCR (sec)
Homocysteine(μmol/L )
Cupper (μgr/dl )

Preeclampsia(Gr I)

Control (Gr II)

n

n

%

70

%

P

60

<48%

37

52.9

2

3.3

<0.001

>48%

33

47.1

58

94.7

<0.001

<58.37

16

22.9

57

95

<0.001

>58.37

54

77.1

3

5

<0.001

<138.48

48

68.6

57

95

<0.001

>138.48

22

31.4

3

5

<0.001

<10.97

50

71.4

57

95

<0.001

>10.97

20

28.6

3

5

<0.001

<159.80

10

14.3

57

95

<0.001

>159.80

60

85.7

3

5

<0.001

aPCR: Activated protein C resistance; PAI-1: Plasminogen activator inhibitor-1
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Table 7. Likelihood ratios of developing preeclampsia with abnormal thrombophilia markers,
homocysteine and copper blood levels.
Parameter

Odds ratio (OR)

Confidence interval (CI)

PAI-1

64.12

17.6 - 232.5

Protein S

32.51

7.36 -143.64

APCR

8.7

2.4- 30.88

Homocysteine

7.6

2.1- 27.1

Cupper

114

29.8- 435.4

aPCR: Activated protein C resistance; PAI-1: Plasminogen activator inhibitor-1

This enabled us to study a well-selected low-risk group of
pregnant women and to minimize the confounding factors
other than thrombophilia, which might increase the risk of
PE occurring.
The mean maternal age in both the PE and the control
groups was similar, supporting the view that age was not a
significant factor in the development of PE, in accordance
with some studies (12) but in contrast to others (13). It
has been argued that current evidence on the association
between maternal age and perinatal outcome remains
largely clouded by age-related confounding factors (14).
High maternal BMI is associated with several pregnancyrelated complications including PE, presumably related to
the presence of insulin resistance and associated endothelial
disorder (15). Our PE patients were not obese but more
overweight than the control group. It has long been known
that environmental influences, such as smoking, alcohol
use, poor nutrition, and thrombophilic state leading to
placental thrombosis have causative roles, not only in
the development of PE, but also in IUGR (16,17). We
recognize that each or both of thrombophilia and PE, by
causing intervillous thrombosis, and consequent placental
perfusion impairment, could be the reason behind IUGR.
This cascade may eventually result in intrauterine fetal
demise and/or PLABR. In accordance with the literature,
we found that out of 70 PE women, 19 (27%) revealed
IUGR fetuses, an additional 2 (2.85%) had intrauterine
ex fetuses, and 2 (2.85%) had PLABR. Such complications
were not encountered in any of our control cases. The
newborns of the PE women in the present study were born
more prematurely, with lower birth weight and with lower
Apgar scores when compared to our control group.
An elevation in Hb or Htc is hypothesized to be the
result of a combination of reduced plasma circulating
volume and enhanced erythropoiesis because of
underlying placental hypoxia. Thrombocytopenia also
accompanies PE and its severity is generally parallel
to that of the underlying disease (18). In our study, PE
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women had significantly higher Hb values and lower PLT
counts than the women in the control group. Although
hyperuricemia (19) and low Alb levels (20) are usually
considered significant indicators of severity of PE and
poor prognosis of perinatal outcome, our PE patients as
compared to controls had similar normal serum levels of
Alb and CR but significantly higher serum levels of UAC.
Although serum UAC and CR are expected to be strongly
interrelated, not all studies demonstrated both to be
elevated (21), including ours, perhaps due to the fact that
serum CR may be a less sensitive marker of hypertensive
disease in pregnancy.
In the present study, we demonstrated that the serum
Cu levels were significantly elevated in PE versus normal
pregnant women, so much so that more than 85% of PE
women revealed levels above the threshold value. The
likelihood ratio of developing PE in women with elevated
Cu levels was 114, being the highest among the parameters
we measured including thrombophilia markers. Although
this finding is very intriguing, it has to be reproduced by
other studies.
Hyperhomocysteinemia has been reported in PE
women (22). Our PE patients also revealed higher Hcy
and lower FOA and B12 levels in accordance with previous
studies. The presence of high Hcy values increased the
relative risk of PE by 1.32–3.2, while the RR reached 9.7
in primiparas and 6.9 in obese patients (23). In the present
study, in primiparas, the likelihood of development of PE
was found to be 7.6 times higher in women with elevated
Hcy serum levels, which were detected in 28.6% of our
PE cases. Furthermore, FBN, Hcy, PAI-1, and aPCR
values were higher and PS values lower in women with
PE in comparison to control group 2. The likelihood
ratios of developing PE with abnormal blood levels of
thrombophilia markers and the percentages of women
with abnormal test results in women with PE were OR
64.12 and 77.1% for PAI-1, OR 32.51 and 47.1% for PS, OR
8.7 and 31.4% for aPCR, and OR 7.6 and 28.6% for Hcy,
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respectively (Tables 6 and 7). Among all the parameters
we studied, serum Cu levels predicted PE the most with an
odds ratio of 114, which was found to be elevated in more
than 85% of PE women. Since mutations in the factor V
mutations are related to aPCR and FVL is reported in
about 90% of patients with aPCR in the general population
(24), we chose to measure aPCR as a marker. In contrast to
some previous studies (25,26), we did not ﬁnd an increased
frequency of suppressed PC and AT III levels in women
with PE as compared to control women.
Several recent meta-analyses that have attempted to
analyze the collective data have reported that pooled OR
for associations between inherited thrombophilia and
PE are generally in the 1.0 to 2.5 range, indicating that
thrombophilia may be only weakly associated with PE, if
at all (26,27). Based on our results, we propose that the
association between thrombophilia, especially through
studying PAI-1 and PS markers, and PE is stronger than
suggested by the majority of publications in the medical
literature. Most important of all, Cu as an independent
marker is selectively and remarkably elevated in PE
women in late pregnancy as compared to normal pregnant
women. If this finding can be reproduced by others and if
serum Cu levels can be demonstrated to begin increasing

in the first trimester before the symptoms and findings of
PE exist, Cu could be a valuable tool to predict PE and
perhaps other complications of pregnancy.
Our study had some limitations such as being done in
a tertiary center, thereby not reflecting the general Turkish
population, and the small number of patients enrolled.
One of the strengths is that potential confounding factors
such as age, ethnicity, and systemic medical problems were
overcome by the homogeneity of this study cohort and the
participation of only primigravid women with no history
of miscarriage.
Whether the association between thrombophilia and
PE is causal or temporal, and more specifically whether
thrombophilia acts as a cofactor in the pathogenesis of
PE or accelerates its course, is speculative. Lastly, our data
should not be considered as a justification for screening for
thrombophilia in normo- or hypertensive pregnant women
since there is no clear evidence that anticoagulation can
prevent PE or improve the outcome.
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